[
  {
    "ts": "2025-12-19T14:50:50+00:00",
    "headline": "Merck (MRK)’s CEO Has a “Better Hand,” Says Jim Cramer",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radar. Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world. Its shares are flat year-to-date and would have been lower had it not been for a run […]",
    "url": "https://finance.yahoo.com/news/merck-mrk-ceo-better-hand-145050125.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "58531d84-3022-30e7-a752-ebc0e29c009a",
      "content": {
        "id": "58531d84-3022-30e7-a752-ebc0e29c009a",
        "contentType": "STORY",
        "title": "Merck (MRK)’s CEO Has a “Better Hand,” Says Jim Cramer",
        "description": "",
        "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radar. Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world. Its shares are flat year-to-date and would have been lower had it not been for a run […]",
        "pubDate": "2025-12-19T14:50:50Z",
        "displayTime": "2025-12-19T14:50:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436",
          "originalWidth": 1280,
          "originalHeight": 853,
          "caption": "Merck (MRK)'s CEO Has a \"Better Hand,\" Says Jim Cramer",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tXp3W2zDkWcbYHYM_edP3Q--~B/aD04NTM7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436.cf.webp",
              "width": 1280,
              "height": 853,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BuRra1_S02PEU8kqjSl2RA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-ceo-better-hand-145050125.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-ceo-better-hand-145050125.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T14:50:22+00:00",
    "headline": "Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ab2a1f66-2aed-3a18-891f-47fc1234232a",
      "content": {
        "id": "ab2a1f66-2aed-3a18-891f-47fc1234232a",
        "contentType": "STORY",
        "title": "Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs",
        "description": "",
        "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]",
        "pubDate": "2025-12-19T14:50:22Z",
        "displayTime": "2025-12-19T14:50:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53",
          "originalWidth": 1000,
          "originalHeight": 668,
          "caption": "Jim Cramer Couldn't Stop Gushing About Johnson & Johnson (JNJ)'s Cancer Drugs",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.1i2Xg8sqkYBwxzkIAC02w--~B/aD02Njg7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53.cf.webp",
              "width": 1000,
              "height": 668,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MUHt2SWlA2SDsXLMEXhTeg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T12:00:00+00:00",
    "headline": "Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2",
    "summary": "MSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studiesThere is no impact on Evaxion’s cash runway which extends to the second half of 2027 COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has bee",
    "url": "https://finance.yahoo.com/news/evaxion-provides-msd-collaboration-retains-120000702.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c9988373-b81e-3556-8458-1c353df589b1",
      "content": {
        "id": "c9988373-b81e-3556-8458-1c353df589b1",
        "contentType": "STORY",
        "title": "Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2",
        "description": "",
        "summary": "MSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studiesThere is no impact on Evaxion’s cash runway which extends to the second half of 2027 COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has bee",
        "pubDate": "2025-12-19T12:00:00Z",
        "displayTime": "2025-12-19T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c9e7552492c4f1a24fb1488cbbdf90ad",
          "originalWidth": 4725,
          "originalHeight": 817,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tYvDc7gSSomQ_rmzZaDHww--~B/aD04MTc7dz00NzI1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c9e7552492c4f1a24fb1488cbbdf90ad.cf.webp",
              "width": 4725,
              "height": 817,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lmeAUk7TMhcgYja38s300g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c9e7552492c4f1a24fb1488cbbdf90ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/evaxion-provides-msd-collaboration-retains-120000702.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/evaxion-provides-msd-collaboration-retains-120000702.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EVAX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T00:25:00+00:00",
    "headline": "Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes",
    "summary": "ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced the closing of a $20 million Series A financing. Proceeds will be used to advance the company’s lead program into Phase 2 clinical development for obesity and diabetes, as well as other programs in IND-enabling stage and early preclinical stage. The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital. “This Seri",
    "url": "https://finance.yahoo.com/news/rezubio-announces-20-million-series-002500188.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "94668ee9-f0b1-3aa3-be4d-a163c5d1562f",
      "content": {
        "id": "94668ee9-f0b1-3aa3-be4d-a163c5d1562f",
        "contentType": "STORY",
        "title": "Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes",
        "description": "",
        "summary": "ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced the closing of a $20 million Series A financing. Proceeds will be used to advance the company’s lead program into Phase 2 clinical development for obesity and diabetes, as well as other programs in IND-enabling stage and early preclinical stage. The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital. “This Seri",
        "pubDate": "2025-12-19T00:25:00Z",
        "displayTime": "2025-12-19T00:25:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/5b7bc3c9378a06f0f9e818ac3da0ba8b",
          "originalWidth": 1045,
          "originalHeight": 322,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_bnmPzEePccFogARfcqd4g--~B/aD0zMjI7dz0xMDQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5b7bc3c9378a06f0f9e818ac3da0ba8b.cf.webp",
              "width": 1045,
              "height": 322,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e.sacMMI1CJ4arMD2IHhxQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5b7bc3c9378a06f0f9e818ac3da0ba8b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rezubio-announces-20-million-series-002500188.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rezubio-announces-20-million-series-002500188.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T14:45:04+00:00",
    "headline": "Here's Why Merck (MRK) is a Strong Growth Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finance.yahoo.com/news/heres-why-merck-mrk-strong-144504838.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "cbd340b2-e95b-3e36-9d10-9ab0e1a122a1",
      "content": {
        "id": "cbd340b2-e95b-3e36-9d10-9ab0e1a122a1",
        "contentType": "STORY",
        "title": "Here's Why Merck (MRK) is a Strong Growth Stock",
        "description": "",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "pubDate": "2025-12-19T14:45:04Z",
        "displayTime": "2025-12-19T14:45:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b",
          "originalWidth": 900,
          "originalHeight": 711,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bjs59nqcRE8iEsudL3mMxA--~B/aD03MTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 900,
              "height": 711,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bro_swiyYm6CQ_YbyBgC9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-merck-mrk-strong-144504838.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-merck-mrk-strong-144504838.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T11:01:21+00:00",
    "headline": "Novo files for CagriSema approval; Merck and Pfizer’s trial win",
    "summary": "Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer trial",
    "url": "https://www.biopharmadive.com/news/novo-cagrisema-merck-pfizer-keytruda-padcev-gsk/808142/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "381d876d-019f-355f-95ed-426d2c5d943c",
      "content": {
        "id": "381d876d-019f-355f-95ed-426d2c5d943c",
        "contentType": "STORY",
        "title": "Novo files for CagriSema approval; Merck and Pfizer’s trial win",
        "description": "",
        "summary": "Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer trial",
        "pubDate": "2025-12-19T11:01:21Z",
        "displayTime": "2025-12-19T11:01:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/novo-cagrisema-merck-pfizer-keytruda-padcev-gsk/808142/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-files-cagrisema-approval-merck-110121453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CAMP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]